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Abstract
Chagas disease is a significant health problem in Latin America and the available treat-
ments have significant issues in terms of toxicity and efficacy. There is thus an urgent need
to develop new treatments either via a repurposing strategy or through the development of
new chemical entities. A key first step is the identification of compounds with anti-Trypano-
soma cruzi activity from compound libraries. Here we describe a hit discovery screening
cascade designed to specifically identify hits that have the appropriate anti-parasitic proper-
ties to warrant further development. The cascade consists of a primary imaging-based
assay followed by newly developed and appropriately scaled secondary assays to predict
the cidality and rate-of-kill of the compounds. Finally, we incorporated a cytochrome P450
CYP51 biochemical assay to remove compounds that owe their phenotypic response to
inhibition of this enzyme. We report the use of the cascade in profiling two small libraries
containing clinically tested compounds and identify Clemastine, Azelastine, Ifenprodil,
Ziprasidone and Clofibrate as molecules having appropriate profiles. Analysis of clinical
derived pharmacokinetic and toxicity data indicates that none of these are appropriate for
repurposing but they may represent suitable start points for further optimisation for the treat-
ment of Chagas disease.
Author Summary
Chagas disease is an important health problem in Latin America. The disease is caused by
the parasite Trypanosoma cruzi, which is transmitted to people via insects of the Triato-
mine family. There are currently only two treatments available, Nifurtimox and Benznida-
zole. These have serious problems including poor efficacy, strain-dependent drug
sensitivity, resistance and toxicity to the patients. There is thus a great need to find new
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drugs for this disease. The first step in a typical drug discovery project is to find com-
pounds that kill the parasite by screening large amounts of compounds in the laboratory.
To do this one requires assays in which the effect of the compounds on the parasites can
be seen. In this paper we describe two assays that together try to identify compounds that
kill T.cruzi parasites. Such compounds are good candidates for further development and
may eventually become new drugs. We tested our assays against a library of compounds
with known clinical activity and identified several interesting hits. As a great deal of data
already exists for these compounds they could potentially be developed into new treat-
ments much faster than completely new compounds.
Introduction
Chagas disease affects approximately 7 to 8 million people in Latin America [1] and a recent
study estimates the mortality rate at 2.78 deaths per 100,000 inhabitants in Brazil [2] resulting
in more than 5000 deaths annually in this country alone. Currently the only drugs approved
for treatment of Chagas disease are the nitrodrugs Benznidazole and Nifurtimox [3]. Both have
significant side-effects and their efficacy for treatment of chronic Chagas disease is unclear
[4,5]. In addition there is naturally occurring resistance to these compounds [6]. Several new
drugs are being developed, mostly targeting the protease cruzipain and the cytochrome p450
enzyme CYP51 (ergosterol biosynthesis pathway) [7,8]. Questions are emerging regarding
CYP51 as a target due to strain-dependent variability in efficacy studies [9], and the recently
reported high failure rate in humans for posaconazole [10–12]. There is thus a need to develop
Chagas drugs with novel mechanisms, improved efficacy and safety profiles [13,14].
The causative agent of Chagas disease is Trypanosoma cruzi. T. cruzimetacyclic trypomasti-
gotes are delivered to humans by infected insects of the Reduviidae family [15] and enter the
cytoplasm of a wide variety of human host cells where they transform into replicative amasti-
gotes. These eventually destroy their host cells and spread throughout the body [16].
The target product profile for new Chagas drugs demands clinical efficacy equal to or
greater than the current nitro drugs [11,17]. In this paper, we present a screening cascade that
details existing and new assays that we have developed to find start points to address the DNDi
target product profile. These involve a high content intracellular primary screen, a novel, high
throughput cidal assay that can be adapted togive an initial estimation of rate of kill together
with a biochemical CYP51 assay to exclude compounds that owe their phenotypic response to
engaging this target.
The development of new drugs from new chemical starting points identified in large scale
screens can take a very long time (>10 years [18,19]). A much faster route is the repurposing of
compounds which already have clinical data associated with them as this allows much faster pro-
gression through the drug development stages [20,21]. We have applied our screening cascade to
identify trypanocidal molecules in a library of 963 clinically tested compounds and identified sev-
eral drugs that had significant effects on T. cruzi growth. Detailed analysis indicates that they
may not represent good repurposing tools. However, their activity, together with good pharma-
cokinetic parameters makes them attractive start points for lead optimisation.
Methods
Reagents
Benznidazole, Nifurtimox, and formaldehyde were obtained from Sigma. Posaconazole was
from Sequoia Research Products. Hoechst 33342 from Life Technologies.
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Cells
Vero cells (ECCAC 84113001) were screened for mycoplasma infection and maintained in
MEMmedium supplemented with Glutamax (Life Technologies) and 10% (v/v) foetal calf
serum (FCS) at 37°C in presence of 5% CO2. T. cruzi parasites (Silvio X10/7 A1, a clonal line
kindly provided by SusanWyllie and Prof. Alan Fairlamb) were maintained in Vero cells. On a
weekly basis emerged trypomastigotes were used to infect a new Vero monolayer at multiplicity
of infection (MOI) 1.5.
Library and compound handling
The compounds tested were obtained from the NIH (Clinical Collection) and from Selleck-
Chem (FDA-approved drug library). Compounds were dispensed into black 384-well assay
plates (Corning) by acoustic dispensing (LabCyte ECHO). The single point primary screen was
carried out at two concentrations (5μM and 15μM). For potency determinations, ten-point one
in three dilution curves were generated, with a top concentration of 50μM. Potencies are
reported as pEC50 (-LOG(EC50[M])).
in vitro T. cruzi assays
For the primary intracellular assay the infection conditions were chosen so that no trypomasti-
gote egress occurs during the compound incubation time. First, Vero cells were infected over-
night with tissue culture derived T. cruzi trypomastigotes in T225 tissue culture flasks (MOI 5).
Next, any remaining free trypomastigotes were washed away with serum free MEM and the
infected Vero cells were harvested by trypsinisation. The infected Vero cells were then plated
into 384-well plates containing the compounds to be tested, at 4000 cells per well in MEM
media with 1% FCS. After 72h incubation at 37°C in presence of 5% CO2, the plates were fixed
with 4% formaldehyde for 20 minutes at room temperature and stained with 5μg/ml Hoechst
33342. The plates were imaged on a Perkin Elmer Operetta high-content imaging system using
a 20x objective. Images were analysed using the Columbus system (Perkin Elmer). The algo-
rithm for the primary assay first identified the Vero nuclei followed by demarcation of the cyto-
plasm and identification of intracellular amastigotes. This algorithm reported mean number of
parasites per Vero cell and total number of Vero cells. Data analysis was as described in [22].
Robust z-factor was calculated with the following formula:
1 ð3  ð1:4826 MAD½0% inhibition ðraw dataÞÞÞ þ ð3  ð1:4826 MAD½100% inhibition ðraw dataÞÞÞ
MEDIAN ½0% inhibition ðraw dataÞ MEDIAN ½100% inhibition ðraw dataÞ
with MAD =Mean Absolute Deviation. Hits from the primary screen were selected based on
the following criteria: T. cruzi activity (percent inhibition)> (median T. cruzi percent inhibi-
tion + 3 x robust Standard Deviation) and Vero activity (percent inhibition)< (median percent
Vero inhibition + 3 x robust Standard Deviation).
Cell replication assessments
Cell replication was assessed under assay conditions following the protocol for the primary
assay described above. At each time-point one 384-well plate was fixed as described above (4,
24, 48, 72, 96 & 120 h) and imaged. Image analysis was as above and total number of Vero cells
and total number of amastigotes in the field of view were counted and plotted against time.
The doubling time for the amastigotes was calculated using the data in the exponential part of
the growth curve.
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Comparison of replication of infected versus non-infected cells was carried out in the same
way (time-points 4, 24, 48 & 72 h) but the image analysis algorithm was modified to count
infected and non-infected cells separately.
Cell replication in non-dividing Vero cells was measured using the same protocol as above
except that the Vero cells were gamma-irradiated (2000 RAD) before infection and infected
cells were plated in 96-well plates at 5x104 cells per well.
Static-cidal assay
The secondary static-cidal assay uses the same protocol as the standard assay with the following
changes: infection is done at MOI 10, and infected Vero cells are incubated 88h at 37°C in pres-
ence of 5% CO2 prior to trypsinisation and plating. Four hours after plating a control plate (no
compounds) was fixed with formaldehyde as described above. Compound containing plates
were fixed after incubation for 96 hours. Compounds are run as ten point dose response curves
in triplicate. The algorithm for the secondary assay was similar to the primary assay but
reported percent infected Vero cells instead of the mean number of parasites. Data was normal-
ised using the following formula:
% Inhibition ¼ 100 ðRaw dataÞ  ð%infected ½50mM Nifurtimox at t ¼ 96hÞð%infected at t ¼ 0hÞ  ð%infected ½50mM Nifurtimox at t ¼ 96hÞ  100
so that compounds that reduce the level of infection over time show a positive result and com-
pounds that allow an increase in infection levels show a negative result.
Rate-of-kill assay
The rate-of-kill assay uses the same protocol as the static-cidal assay but plates are incubated
for 24, 48, 72 and 96 hours prior to fixing. Percent infected data is plotted as a time-course for
each compound at every concentration. The minimum cidal concentration (MCC) is defined
as the lowest concentration of compound that clears at least half as many Vero cells of intracel-
lular parasites as Nifurtimox (50μM) within the timeframe of the assay.
CYP51 assay as described in [23].
H1-receptor binding studies: Inhibition of agonist-induced calcium flux was measured in CHO
cells expressing the H1-receptor using the method described in [24].
Results
High-content assay design
A high-content screening assay for intracellular T. cruzi amastigotes was developed based
on previously published methods [25–27]. An outline of the assay is shown in Fig 1A and a
detailed description of the assay can be found in the methods section. The only fluorescent
marker used in this assay is a DNA stain. This allows usage of any T. cruzi strain and host
cell line combination. Plates were imaged on an automated microscope and the images
were analysed with an image analysis algorithm that we designed using Perkin Elmer
Columbus (Fig 1B and methods). We determined the effect of DMSO on the assay and
found that there was a stimulation of T. cruzi growth up to 0.5% DMSO followed by an
increasingly detrimental effect at higher concentrations (Fig A in S1 Text). This profile was
deemed compatible with compound screening and profiling as we use 0.5% DMSO as stan-
dard. Using the assay we determined the potency of several compounds with known anti-
New Trypanosoma cruzi Hit-Discovery Screening Cascade
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T. cruzi activity and found potencies that are in line with the literature [25,28,29]
(Table 1).
Cell replication in the assay
To avoid a dilution effect of the T. cruzi amastigotes by Vero cell division we limited Vero cell
division during the assay by reducing the amount of foetal calf serum from 10% to 1% and by
plating the host cells near confluency. Under these conditions Vero cell division was measure-
able but minimal (Td = 85h) and the T. cruzi X10/7 A1 amastigote doubling time in exponen-
tial phase was 13.5h (Fig 2A). A separate experiment using irradiated Vero cells to completely
block Vero cell replication yielded a T. cruzi amastigote doubling time of 11.2h (Fig 2B).
Assay performance
To assess the suitability of the assay for high-throughput screening we determined standard
screening statistics across 344 384-well plates (Table 2). The data show that the assay is robust,
Fig 1. T. cruzi primary screening assay. Panel A. Schematic outline of the primary screening assay.
Numbers are time in hours. Panel B. Image acquisition and analysis. Left-hand side shows an image as
obtained from the high-content microscope. The large structures are the nuclei of the host cells and the small
punctate structures are the nuclei of the amastigotes. The right-hand panel shows the segmentation carried
out by the image analysis algorithm. The nuclei are delineated in red, the Vero cell cytoplasm in white and the
amastigotes in yellow.
doi:10.1371/journal.pntd.0004584.g001
Table 1. Potencies against intracellular T. cruzi for control compounds (N = 3).
Compound Mean pEC50 StDev EC50 (μM)
Posaconazole 9.0 0.1 0.001
Ketoconazole 8.7 0.1 0.002
Nifurtimox 6.6 0.04 0.26
Benznidazole 6.3 0.02 0.49
doi:10.1371/journal.pntd.0004584.t001
New Trypanosoma cruzi Hit-Discovery Screening Cascade
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004584 April 15, 2016 5 / 19
Fig 2. Replication of host cells and amastigotes. Panel A. A time-course was carried under assay
conditions and plates were fixed every day followed by imaging and analysis. The full circles show the host
cell counts and the open circles show the amastigote counts (n = 384 wells, error bars are standard
deviations). The doubling time for the amastigotes was determined in the exponential growth window
(between 24 and 96 h). Panel B. A time-course was carried out using gamma-irradiated Vero cells. Plates
were fixed every day followed by imaging and analysis. The full circles show the host cell counts and the
open circles show the amastigote counts (n = 18 wells from a single experiment, error bars are standard
deviations).
doi:10.1371/journal.pntd.0004584.g002
Table 2. Performance statistics of the T. cruzi assay.
Robust Z-factor 0.8 +/- 0.1 (n = 344)
Coefﬁcient of Variation [%] 9.8 +/- 2.8 (n = 344)
Signal to Background 31 +/- 13 (n = 344)
Percent Infected Cells 27% (n1x106)
Amastigotes / vero cell 6.8 +/- 3 (n = 344)
Throughput 40 x 384 well per batch
Values are averages +/- standard deviation, n is number of plates for Z-factor, %Coefﬁcient of Variation,
Signal:Background (S:B) and Amastigotes / vero cell (calculated from 32 control wells on each plate,
includes both infected and non-infected cells) and number of Vero cells for Percent Infected Cells.
Coefﬁcient of Variance is for infected vehicle control wells. For S:B, signal is average number of
amastigotes / Vero cell in vehicle control wells, background is average number of amastigotes / Vero cell in
100% effect (50μM Nifurtimox) control. Percent Infected cells and Amastigotes / Vero cell were determined
at 72h.
doi:10.1371/journal.pntd.0004584.t002
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has low variability and a high signal to background. We achieved a throughput of 15,360 wells
per batch while maintaining high-quality performance statistics. This allows the determination
of 14,080 single point measurements (for library screening) or up to 1,280 potency determina-
tions in a single run.
Static-cidal assay
To assess screening hits for their ability to be cytocidal rather than cytostatic or growth slowing
we developed a medium throughput (400 compounds / batch) assay to predict cidality of com-
pounds against intracellular T. cruzi. This assay is similar to the primary assay described above,
but has an increased parasite load in the cells resulting from extending the time after infection
before compound exposure and the use of a higher MOI (Fig 3A). The reason for increasing
the parasite load is that in the primary assay we only see a few parasites (typically2) in each
infected cell after overnight infection. This low level of infection means that it is difficult to dis-
tinguish static from cidal compounds at the end of the assay (Fig 3B left panel). As shown in
Fig 3B right panel, increasing the parasite load (to ~15 amastigotes / cell) increases the window
between the detection limit of the assay and the starting burden and therefore allows much bet-
ter separation between static and cidal compounds. We could not use the same image analysis
approach as used for the primary assay as the number of parasites per cell becomes too high to
segment the amastigotes reliably. Instead we developed an algorithm that assesses whether a
Vero cell is infected or not, and we used the percentage of infected cells as primary measure-
ment for the static-cidal assay. In order to readily identify cidal compounds we normalised the
raw data using the starting level of infection as 0% effect and the final level of infection in pres-
ence of 50μMNifurtimox as 100% effect control. As a result, compounds which do not change
the level of infection give a maximum percent inhibition (MAX PI) of 0, compounds that allow
progression of infection give a negative MAX PI and compounds that are likely to be cidal give
a positive MAX PI. The results from this assay for nifurtimox, benznidazole and posaconazole
are shown in Fig 3C and Table 3. MAX PI for both nifurtimox and benznidazole is around
100% inhibition, while it only reaches 60% for posaconazole in the 96h timeframe of the assay.
To obtain rate-of-kill information we carried out the static-cidal assay in timecourse format
(Fig 4A), with timepoints taken every 24h. Due to the high level of infection at the start of the
assay a cycle of trypomastigote release (and Vero lysis) occurs during the timecourse. The
resulting re-infection leads to a significant increase in the percentage of infected cells during
the course of the experiment (Fig 4B and 4C). Fig 4C shows the results of the rate-of-kill assay
for nifurtimox, benznidazole and posaconazole. Nifurtimox and benznidazole exhibit similar
kill profiles, with killing seen from 24h onwards and a final residual level of infection of ~8%.
While posaconazole was much more potent in terms of EC50, it appears to be slower acting
with a later onset of cidal activity and a higher level of infection at the end of the assay (~15%).
We calculated the minimum cidal concentration (MCC) as the lowest concentration tested
that resulted in a significant decrease in percentage of infected cells (see materials and meth-
ods). The pMCCs (-LOG(MCC[M]) for the control compounds are shown in Table 3. To con-
firm that a reduction in the percentage of infected cells was not merely due to a lower
replication rate of infected Vero cells relative to non-infected Vero cells, we assessed replication
of both types of cells and found that infected cells divide as well as or better than non-infected
cells (Fig B in S1 Text).
Together the assays described above constitute our in vitro screening cascade for T.cruzi
(Fig 5). The cascade is tailored so that the initial assays provide the high throughput required
for library screening, while the secondary assays have lower, but sufficient throughput to give
key information regarding cidality and rate-of-kill for the hit compounds from the primary
New Trypanosoma cruzi Hit-Discovery Screening Cascade
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screen. The cascade also includes a biochemical CYP51 assay to assess whether compounds act
through this mode of action.
Bio-actives library screen
We used the screening cascade to profile two sets of compounds that have known bio-activity
and associated clinical data. The SelleckChem set contains 421 FDA-approved drugs and the
NIH Clinical Collection set consists of 727 compounds that have been used in clinical trials.
These libraries were tested in single replicate at 5 and 15 μM. Fig 6 panels A&B show the results
for both screens. As expected there were substantially more compounds with toxicity towards
the Vero cells at 15 μM (20% of all compounds) then at 5 μM (11%) (using an arbitrary Vero
percent inhibition cut-off of 30%). Panel C shows the relationship between T. cruzi inhibition
at 5 and 15 μM and shows that there was good correlation between both screens with an
expected shift to higher activity at 15 μM.We also repeated a set of compounds at 5 μM to
Fig 3. Static-cidal assay. Panel A. Schematic outline of the static-cidal screening assay. Numbers are time
in hours. Times above the timeline are from addition of trypomastigotes, times below the line are starting from
addition of the infected cells to the plates containing compounds. Panel B. Schematic outlining the
differences between the primary (left) and the static-cidal (right) assays. The blue line represents an
untreated sample, the red line a sample treated with a static acting compound and the green line a cidal
compound. The x-axis is time (h) and the y-axis parasite load (amastigotes per Vero cell for the screening
assay, percent infected Vero cells for the static-cidal assay). These charts do not represent data, they are
models to explain the why there was a need to develop the static-cidal assay. The dashed line represents the
detection limit of the assay. The locations of the 0% and 100% controls as used for data normalisation and
curve fitting are shown. Panel C. Static-cidal assay dose-response curves for nifurtimox (black circles),
benznidazole (red triangles) and posaconazole (green squares) x-axis shows concentration of compounds,
y-axis percent inhibition normalised to starting level of infection (0% effect) and level of infection at 96h in
presence of 50μM nifurtimox (100% effect).
doi:10.1371/journal.pntd.0004584.g003
Table 3. Static-cidal (SC), Rate-of-kill (RoK) and CYP51 results for control compounds and selected
hits from the bio-actives screen.
Compound MAX PI (SC)1 pMCC (RoK) CYP51 pIC50
Nifurtimox 103 5.3 < 5
Benznidazole 91 4.8 < 5
Posaconazole 59 7.0 7.5
Ketoconazole 61 8.1 7.9
Clotrimazole 60 7.6 7.4
Bifonazole 69 7.2 7.4
Itraconazole 71 7.2 7.5
Econazole 63 7.2 7.6
Voriconazole 70 7.2 7.4
Clemastine 108 6.7 < 5
Azelastine 106 5.7 < 5
Amlodipine 113 5.7 < 5
Ifenprodil 117 5.7 < 5
Ziprasidone 111 5.3 < 5
Cloﬁbrate 116 4.8 < 5
Abiraterone 60 4.3 <6
Nilotinib 38 N/A 6.8
1 Maximum Percent Inhibition in the static cidal assay, only derived from compound concentrations that are
not toxic to the host cells.
doi:10.1371/journal.pntd.0004584.t003
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assess reproducibility, and as shown in panel D there was a good correlation between the two
independent replicates (R2 = 0.86). In order to select hits for follow-up we set criteria for both
T. cruzi activity and Vero toxicity. Hits were defined as causing a statistically significant
Fig 4. T. cruzi rate-of-kill assay. Panel A. Outline of the rate-of-kill assay. Numbers are time in hours. Times
above the timeline are from addition of the trypomastigotes, times below the line are starting from addition of
the infected cells to the plates containing compounds. Panel B. Representative images from untreated wells
in the static-cidal assay at the different time-points. Panel C. Rate-of-kill profiles. Left panel shows percent
infected cells against time, right panel shows Vero counts against time (n = 3, error bars = standard deviation)
for Nifurtimox (top), Benznidazole (middle) and Posaconazole (bottom). Concentrations are as follows (μM)
(all compounds were tested at the same concentrations except for Posaconazole, its concentrations are
shown between brackets): black circle 50 (1), red triangle 17 (0.3), green square 5.6 (0.1), yellow diamond
1.9 (0.04), blue triangle 0.6 (0.01), pink hexagon 0.2 (0.004), cyan circle 0.07 (0.001), triangle dark yellow 0.
doi:10.1371/journal.pntd.0004584.g004
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reduction of T. cruzi amastigotes with no statistically relevant toxicity (further defined in Meth-
ods section). This selection procedure yielded 75 hits, which are marked green on Fig 6A. Some
compounds appeared more than once because they were present in both compound libraries.
After removing the duplicates there were 69 hits left. Grouping of the hits by target area
showed that a large subset of the hit compounds target the CNS (40%), followed by calcium
channel inhibitors and antifungals (Fig 7A). We next carried out 10-point dose-response
curves on the hits to determine the T. cruzi and Vero cell pEC50s (Table A in S1 Text). Fig 7B
shows the distribution of potencies found for the hit compounds. Most compounds only had
moderate activity with the mode of the distribution being pEC50 5.3 (EC50 = 5.6 μM). A small
subset of compounds had much better activity, with seven compounds showing a pEC50> 7.
All these compounds are azoles known to inhibit the enzyme lanosterol-14-demethylase
(CYP51) [30,31].
We next assessed selected potent and selective hits from our screen in the static-cidal and
CYP51 assays (Table 3). In the static-cidal assay we observed clear differences in maximum
inhibition ranging from 38% for nilotinib to 117% for ifenprodil. As expected, the azoles
showed strong CYP51 inhibition as did nilotinib. While the CYP51 azoles showed high
potency in the primary assays we found that in the static-cidal assay the maximum level of
activity achieved was poor compared to most other compounds tested (Fig 8A). Rate-of-kill
profiles were also determined and examples are shown in Fig 8B; ziprasidone showed fast onset
Fig 5. T.cruzi screening cascade. Schematic of T.cruzi screening cascade. Primary assay is the high-
content intracellular amastigote assay at a single concentration. Compounds that achieve a set level of
inhibition of amastigotes and show no toxicity against the host cells are progressed to potency determination
in the same assay (using 10 compound concentrations). A potency and selectivity cut-off are next applied
(cut-offs vary based on library used, MW of compounds, etc.) and the most promising compounds are
progressed to the static-cidal assay to predict cidality and to the CYP51 assay to identify any compounds that
may act through this target. Compounds that are predicted to be cidal and CYP51 independent are further
progressed into the rate-of-kill assay and eventually into a hits-to-lead programme.
doi:10.1371/journal.pntd.0004584.g005
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of cidality, azelastine a more delayed response and nilotinib a much slower rate (this com-
pound did not reach the threshold for cidality over the timecourse of the assay). All the CYP51
inhibitors showed a similar profile to posaconazole. As the static-cidal and rate-of-kill assays
are carried out at 10 concentrations for each compound we could use the data to determine
EC50s and MCCs and compared them to the results from the primary assay. We found that the
EC50s from the primary and static-cidal assays were similar (Fig 6C left panel). Fig 6C right
panel shows that the rate-of-kill assay MCC and static-cidal EC50 also correlate, with the MCC
on average 0.6 LOG units lower than the EC50.
Azelastine
One of the compounds with an interesting profile was azelastine, an antihistamine that acts
through inhibition of the histamine H1 receptor [32]. As a chemotype, these have been
Fig 6. Results of clinical collection compound primary screen. Panel A. Scatterplot representing the results for the screen at 5 μM. Green circles
represent the hits, blue circles are all the other compounds. Panel B. Scatterplot representing the results for the screen at 15 μM. Green circles represent the
hits from the 5 μM screen, blue circles are all the other compounds. Panel C. Scatterplot comparing T. cruzi percent inhibition between 5 μM and 15 μM
screens. Panel D. Replicates plot for a subset of compounds screened twice at 5 μM (n = 579, R2 = 0.86).
doi:10.1371/journal.pntd.0004584.g006
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previously described as having trypanocidal activity [25,33]. To assess if the antitrypanosomal
activity of this compound can be separated from its H1 activity we assessed the H1 and T. cruzi
activity for a set of azelastine analogues (Fig C and Table B in S1 Text) and found that H1 bind-
ing could be significantly reduced (>1000-fold) while maintaining T.cruzi activity.
Discussion
In order to find start points for drug discovery a suite of assays is required that combine disease
relevance and scale to allow the iterative deselection of chemotypes with inappropriate proper-
ties. Here we describe the use of a T. cruzi screening cascade to identify new repurposing candi-
dates for the treatment of Chagas disease. The cascade consists of a single-point primary
screen, followed by potency determination, a cidality and rate-of-kill assessment and in vitro
CYP51 activity assessment (Fig 5).
Various in vitro assays have been used as a primary screen to identify compounds that kill
T. cruzi. Axenically grown epimastigotes as a surrogate for the disease relevant stages of the dis-
ease have been developed as they are more amenable to high-throughput screening [34–36].
Fig 7. Analysis of the hits. Panel A. All the hits from the 5 μM screen were annotated with a general
pharmaceutical class. The chart shows the frequency for each class. Panel B. The potencies for all the hits
were determined and represented as a frequency table. Bars in red represent CYP51 inhibitors, green = all
other classes).
doi:10.1371/journal.pntd.0004584.g007
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Fig 8. Static-cidal results for hits from the screen. Panel A. Maximum percent inhibition seen in static-
cidal assay relative to Nifurtimox at t = 96h (100%) and t = 0h (0%). The data-set is split in half; the CYP51
inhibitors are marked in green, the other compounds in blue. Panel B. Static-cidal profiles for 3 of the hits:
Ziprasidone (Zp), Azelastine (Az) and Nilotinib (Nl). Infection curves at concentrations that were toxic to the
host cells are shown in light grey instead of black. Concentrations are as follows (μM): black circle 50, red
triangle 17, green square 5.6, yellow diamond 1.9, blue triangle 0.6, pink hexagon 0.2, cyan circle 0.07,
triangle dark yellow 0. Panel C. Left panel: scatterplot comparing the potencies obtained in the primary
screening assay (x-axis) with the potencies obtained in the static-cidal assay (y-axis). A linear regression was
fitted to the data (R2 = 0.92). Right panel: scatterplot comparing the potencies obtained in the static-cidal
assay (x-axis) with the minimum cidal concentration (y-axis) obtained in the rate-of-kill assay. A linear
regression was fitted to the data (R2 = 0.96). Panel C:
doi:10.1371/journal.pntd.0004584.g008
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However, using the insect stage of T. cruzi increases the risk of not assessing the relevant biol-
ogy. With that in mind there has been a recent transition to assaying intracellular parasites
using reporter systems and high-content screening methods [25,26,37–43].
Our primary screening assay is distinct from previously published T. cruzi high-content
assays in that we infect the Vero cells in bulk and then plate infected Vero cells into 384-well
plates containing compounds [25,26,38,42]. This is important in terms of streamlining the
screening process and allows us to run this assay at relatively high throughput (~14,000 wells /
run). These changes have not affected the results produced by the assay as the potencies that
we determined for standard compounds and for the screening hits align well with previously
published results (see below).
Our previous experience in finding startpoints for kinetoplastid drug discovery has
highlighted the issue of separating growth-slowing from cytocidal compounds [44,45]. We
have observed significant replication of the T. cruzi amastigotes in the assay described here (Fig
2) which contrasts with our intracellular Leishmania assay, where we see almost no replication
[22]. This combined with a low level of infection means that our T. cruzi high-throughput
assay is poor at distinguishing static from cidal compounds (Fig 3B). We have therefore devel-
oped a secondary assay to assess whether compounds act through a cidal mechanism or not
(Fig 3). This assay is different from previously published cidality assays in that it is much
shorter, has far higher throughput and does not include a washout step [46,47]. It represents a
pragmatic answer to deselecting chemotypes with inappropriate mechanisms of action early
and efficiently. By limiting compound numbers but taking more time-points, the assay can be
configured to give an indication of rate of kill. While we currently don’t have enough data to
assess how cidality and rate-of-kill relate to in vivo efficacy, from a pragmatic point of view we
prioritise predicted cidal compounds over static ones and fast acting over slower acting which
is in line with compound progression criteria proposed by the Drugs for Neglected Diseases
initiative (DNDi) [11]. We have previously shown that a similar static-cidal assay for Trypano-
soma brucei provides superior predicting power of in vivo efficacy in an animal model com-
pared to the primary assay [48]. However, as our static-cidal assay only gives a prediction
regarding the cidal nature of a compound, further verification of the most interesting series in
a low throughput washout experiments will be valuable.
A key measurement returned by the static-cidal assay is the minimum cidal concentration
(MCC). This is the lowest concentration of compound necessary to see cidal activity in the
assay. We observed that around 3-fold more compound is required to reach the MCC com-
pared to the EC50. This is not surprising as one would expect to see cidal activity near the EC99
of a compound rather than the EC50.
We employed the above screening cascade to screen two libraries containing molecules with
known clinical data with an eye on identifying candidates for repurposing towards the treat-
ment of Chagas disease. We carried out this screen at two concentrations (5 and 15 μM) and
the comparison between these two runs exemplifies the difficulty of choosing a suitable screen-
ing concentration when working with intracellular parasites. A higher concentration increases
the hit-rate and allows finding less potent hits, but also increases the risk of toxicity towards
the host cell which would hide any potential anti-parasitic activity at lower concentrations (Fig
6C).
The potency of most hits proved to be modest, with the exception of the CYP51 inhibitors
which were very potent (Fig 7B). We found 11 hits that were previously shown to have activity
against T. cruzi and the potencies we measured correlated well with the published values (R2 =
0.7)[25].
In spite of their high potency, the CYP51 inhibitors all exhibited a moderately slow killing
profile resulting in a relatively high number of infected cells remaining at the end of the static-
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cidal assay timecourse (reflected by poor level of inhibition, Fig 8A). The discrepancy between
potency and rate-of-kill is not unexpected as potency reflects the affinity for the target(s) and
the concentration of the compound inside the amastigote whereas the rate-of-kill reflects the
mode-of-action (MOA) of the compound. Targeting some MOAs will result in fast, replication
independent cell death (membrane integrity, non-specific toxicity, etc) whereas others will
require a certain amount of cell division before the cells start dying (enzymes in biosynthetic
pathways, slow turnover targets, etc). Our results suggest that the CYP51 inhibitors fall in the
second category while the nitrodrugs fall in the first one. Whether the poor performance of the
CYP51 inhibitors in T. cruzi clinical trials is related to this or to other factors (e.g. pharmacoki-
netics) remains to be ascertained.
We classified the remaining hits from the screen and found that many are CNS targeting
lipophilic amines. As the targets for such drugs do not exist in T. cruzi amastigotes or Vero
cells these are likely to be off-target driven. This category of molecules is known to be particu-
larly promiscuous [49]. Because of their low therapeutic dosage and potential side-effects these
may not be a progressable family of hits. More interesting is the observation that many calcium
channel blockers were identified. This supports the idea that interfering with Ca2+ homeostasis
may be a good approach for T. cruzi chemotherapy [50]. In addition we identified many
CYP51 inhibitors which were already known to have anti-T. cruzi activity.
In this report we have identified several known clinical compounds as candidates for a
repurposing strategy for Chagas disease, some of which were also identified in independent
screening efforts [25,33,51]. Based on the profiles shown (potency, selectivity and cidality) the
most promising drugs are clemastine, azelastine, ifenprodil, ziprasidone and clofibrate. Phar-
macokinetic data in humans exists for these molecules [32,52–55]. They all have reasonable
oral bioavailability but the free blood concentrations achievable are currently limited by toxic-
ity, normally associated with their primary human target. While this means that these mole-
cules are not suitable for repurposing, the H1 antagonists in particular look very attractive as
start points for optimisation. Either removing the H1 antagonism using the large quantity of
data on the H1 pharmacophore or eliminating CNS penetration would give the potential for
developing effective Chagas treatments. We tested a panel of azelastine analogues and show
that the T.cruzi activity can indeed be separated from H1 antagonism (Fig C in S1 Text).
In conclusion, the novel screening cascade for Chagas hit-discovery described here allows
high-throughput screening of large compound collections through a robust high-content intra-
cellular assay. In a second step, non-cidal compound classes are removed at a lower, but still
significant, throughput. In addition the cascade includes a CYP51 assay to assess whether the
compounds act through this mode-of-action. The combination of these assays allows selection
of the most promising chemotypes for further development.
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